LongBio Pharma's LP-005 achieves 100% transfusion avoidance in Phase II PNH trial

• LongBio Pharma reported Phase II results for LP-005 in paroxysmal nocturnal hemoglobinuria in China on October 21, 2026.
• The 30-patient trial used intravenous dosing every four weeks; no treatment-related serious adverse events were reported.
• At week 12, hemolysis control reached 100% in both the 1,200 mg and 1,500 mg groups.
• At week 24, 85.7% of patients (6/7) receiving 1,500 mg achieved hemoglobin increases of at least 2 g/dL without transfusion.
• All three dose groups achieved 100% transfusion avoidance at week 12, with no breakthrough hemolysis observed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261021-12377895), on October 21, 2026, and is solely responsible for the information contained therein.